KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib (Q21563446)

scientific article

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Language	Label	Description	Also known as
English	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib	scientific article	KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Statements

1 reference

13 November 2016

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib (English)

1 reference

13 November 2016

1 reference

10

Harold E Varmus

Harold E

Varmus

1 reference

2 September 2022

1

William Pao

William

Pao

1 reference

2 September 2022

6

Marc Ladanyi

Marc

Ladanyi

1 reference

2 September 2022

9

Mark G Kris

Mark G

Kris

1 reference

2 September 2022

3

Gregory J

Riely

Gregory J Riely

1 reference

2 September 2022

5

Qiulu

Pan

Qiulu Pan

1 reference

2 September 2022

7

Maureen F

Zakowski

Maureen F Zakowski

1 reference

2 September 2022

8

Robert T

Heelan

Robert T Heelan

1 reference

2 September 2022

Theresa Y Wang

2

Theresa Y

Wang

1 reference

2 September 2022

Vincent A Miller

series ordinal

4

author given names

Vincent A

author last names

Miller

1 reference

2 September 2022

language of work or name

English

0 references

publication date

January 2005

0 references

published in

PLOS MEDICINE

0 references

volume

2

0 references

page(s)

e17

0 references

issue

1

0 references

copyright license

Creative Commons Attribution 4.0 International

start time

25 January 2005

1 reference

stated in

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545207

retrieved

19 March 2017

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545207

retrieved

19 March 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545207

retrieved

19 March 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545207

retrieved

19 March 2017

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545207

retrieved

19 March 2017

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545207

retrieved

12 September 2017

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545207

retrieved

12 September 2017

The ras oncogenes in human lung cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545207

retrieved

12 September 2017

Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545207

retrieved

30 May 2018

Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=545207

retrieved

30 May 2018

Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15696205

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15696205

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1371/JOURNAL.PMED.0020017

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

881523

OpenCitations bibliographic resource ID

881523

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

881523

ResearchGate publication ID

8036874

0 references

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib (Q21563446)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib (Q21563446)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search